CNS-IPI (CNS International Prognostic Index for DLBCL)
Estimates the risk of central nervous system relapse or progression in adults with diffuse large B-cell lymphoma on R-CHOP-like immunochemotherapy, stratifying patients to help identify candidates for CNS evaluation or prophylaxis.